OSCR analyst estimates
Oscar Health (OSCR) analyst ratings, the average price target and its range, and every firm's latest call.
OSCR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Oscar Health price target raised to $36 from $26 at UBS | $36.00 |
| Sep 18, 2026 | Raymond James | Oscar Health price target raised to $42 from $34 at Raymond James | $42.00 |
| Sep 17, 2026 | UBS | Oscar Health Inc (OSCR) PT Raised to $30 at BofA Securities | $30.00 |
| Sep 17, 2026 | Barclays | Oscar Health price target raised to $49 from $39 at Barclays | $49.00 |
| Sep 17, 2026 | Goldman Sachs | Oscar Health price target raised to $34 from $30 at Goldman Sachs | $34.00 |
| Sep 17, 2026 | Robert W. Baird | Oscar Health price target raised to $33 from $27 at Baird | $33.00 |
| Sep 17, 2026 | Piper Sandler | Oscar Health Inc (OSCR) PT Raised to $48 at Piper Sandler | $48.00 |
| Aug 11, 2026 | Goldman Sachs | Oscar Health price target raised to $30 from $22 at Goldman Sachs | $30.00 |
| Aug 7, 2026 | Robert W. Baird | Oscar Health price target raised to $27 from $19 at Baird | $27.00 |
| Aug 6, 2026 | Barclays | Oscar Health price target raised to $39 from $35 at Barclays | $39.00 |
| Jul 28, 2026 | Piper Sandler | Oscar Health price target raised to $36 from $26 at Piper Sandler | $36.00 |
| Jun 15, 2026 | Raymond James | Raymond James on Court Ruling: 'This should be viewed as a positive OSCR and other ACA exchange players as this puts to bed the $5 rule' | $30.00 |
| Jun 10, 2026 | Barclays | Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation' | $35.00 |
| Jun 4, 2026 | Wells Fargo | Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight | $20.00 |
| May 26, 2026 | Barclays | Oscar Health price target raised to $30 from $21 at Barclays | $30.00 |
- 10 firms rate OSCR: 3 buy, 6 hold, 1 sell.
- The average price target is $37.43 from 7 analysts, from $20.00 to $49.00.
Updated 2026-11-07 11:53 UTC